Early detection of pancreatic cancer by comprehensive serum miRNA sequencing with automated machine learning
Munenori Kawai(Unknown), Hiroshi Seno(Kyoto University), Toshihiro Morita(Harvard University), Ryuki Minami(Tenri Hospital), Kosuke Minaga(Kindai University), Chiharu Kawanami(Otsu Red Cross Hospital), Takahisa Maruno(Kyoto University), Masaya Ohana(Tenri Hospital), Masatoshi Kudo(Kindai University), Tomohiro Watanabe(Kindai University Sakai Hospital), Atsushi Umemura(University of California San Diego), Yuki Nakanishi(Kyoto University Hospital), Makoto Sono(Kyoto University), Kenta Mizukoshi(Kyoto University), Yoshito Ito(Kyoto Prefectural University of Medicine), Yoshito Uenoyama(Japanese Red Cross Society Wakayama Medical Center), Naoki Kanda(Jichi Medical University), Akihisa Fukuda(Kyoto University), Yoshitaka Nakai, Toshinao Itani(Kobe City Nishi-Kobe Medical Center), Mio Namikawa(Kyoto University), Hiroyuki Marusawa, Munemasa Nagao(Kyoto University), Mitsuharu Hirai(Arkray (Japan)), Masanori Asada(Kyoto University), Kosuke Iwane(Kyoto University), Yuki Yamauchi(University of Tsukuba), Yukitaka Yamashita(Miyagi Prefectural Hospital Organization), Toshiyuki Kimura(Hokuriku University), Takuto Yoshioka(Takatsuki Red Cross Hospital), Kozo Ikuta(Shinko Hospital), Ryo Otomo(Iwate Medical University), Shigehiko Fujii(Dokkyo University), Nobuhiro Hieda(Otsu Red Cross Hospital), Yutaka Takada(Kyoto University), Go Yamakawa(Kyoto University), Seiji Shio(Shinko Hospital), Kazuyoshi Matsumura(Shiga Medical Center), Shujiro Yazumi(Kitano Hospital), S. Obata(Arkray (Japan)), Saiko Marui
Cited by 31
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k